The analysis of chemokines and Epstein-Barr virus in the tumor genesis of primary central nervous system lymphomas
Project/Area Number |
20500327
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Nerve anatomy/Neuropathology
|
Research Institution | Kurume University |
Principal Investigator |
YASUO Sugita Kurume University, 医学部, 教授 (80216316)
|
Co-Investigator(Kenkyū-buntansha) |
大島 孝一 久留米大学, 医学部, 教授 (50203766)
寺崎 瑞彦 久留米大学, 医学部, 准教授 (70320223)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | 神経科学 / 脳神経疾患 / 病理学 |
Research Abstract |
In this study, Epstein-Barr virus (EBV) was implicated in the pathogenesis of primary central nervous system lymphomas (PCNLs) in immunocompetent hosts (elderly immunocompetent patients ; age≧60 years). Histologically, all cases were diagnosed as diffuse large B-cell lymphoma with extensive necrosis. EBV subtyping-PCR analysis demonstrated that many cases were EBNA 2A type and showed 30-bp LMP-1 deletion on PCR analysis. These results indicate that LMP-1 deletion may have more potent tumor-promoting activity than EBV containing the full-size LMP-1 gene in the pathogenesis of PCNLs in immunocompetent hosts. In addition, some EBV subtypes may show more potent tumor-promoting activity. Regarding chemokines, we have shown that CXCL12/CXCR4 was frequently expressed in PCNLs and other brain cells. Thus, the results suggest that the CXCL12/CXCR4 signaling mediates PCNLs development.
|
Report
(4 results)
Research Products
(12 results)